Methods and Pharmaceutical Compositions for Treating Human Immunodeficiency Virus Type 1 (HIV-1) Infections

Abstract

The present invention provides methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (HIV-1) infections. In particular, the present invention relates to a method for treating HIV-1 infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an inhibitor of SGT1 activity or expression.

Claims

1. A method for treating HIV-1 infection in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an inhibitor of suppressor of G2 allele of SKP1 (SGT1) activity or expression.

2. The method of claim 1 wherein the inhibitor of SGT1 expression is selected from the group consisting of antisense RNA molecules, antisense DNA molecules, small inhibitory RNAs (siRNAs), short hairpin RNA and ribozymes.

3. The method of claim 1 wherein the inhibitor of SGT1 activity or expression is used in combination with at least one antiretroviral.

4. The method of claim 3 wherein the antiretroviral is selected from the group consisting of nucleoside/nucleotide reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), entry inhibitors, integrase inhibitors, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors phosphonate reverse transcriptase inhibitors, compounds of the TIBO (tetrahydro-imidazo[4,5,1-jk][1,4]-benzodiazepine-2(1H)-one and thione)-type compounds of the [alpha]-APA ([alpha]-anilino phenyl acetamide) type inhibitors of trans-activating proteins, protease inhibitors fusion inhibitors, CXCR4 receptor antagonists, inhibitors of a viral integrase; and ribonucleotide reductase inhibitors.

5. A method for screening a drug for the treatment of an HIV-1 infection comprising the steps of i) providing a candidate compound ii) determining whether the candidate compound is an inhibitor of SGT1 activity or expression and iii) positively selecting the candidate compound which is an inhibitor of SGT1 activity or expression.

6. The method of claim 5 wherein step ii) comprises the following steps: (1) infecting cultured mammalian cells with HIV-1 virus; (2) bringing into contact the infected cells obtained at steps (1) with a candidate compound that has been positively selected; (3) determining the HIV-1 replication; and (4) comparing the HIV-1 replication determined at step (3) with the HIV-1 infectivity that is determined when step (2) is performed in the absence of the said positively selected compound

7. The method of claim 6 wherein step (2) is performed before step (1).

8. The method of claim 4, wherein the NNRTI is efavirenz, etravirine or nevirapine.

9. The method of claim 4, wherein the PI is atazanavir, darunavir or ritonavir.

10. The method of claim 4, wherein the entry inhibitor is enfuvirtide or maraviroc.

11. The method of claim 4, wherein the integrase inhibitor is dolutegravir or raltegravir.

12. The method of claim 4, wherein the antiretrivurak is pentamidine, thymopentin, castanospermine, dextran or foscarnet-sodium.

13. The method of claim 4, wherein the nucleoside reverse transcriptase inhibitor is zidovudine, didanosine, zalcitabine, lamivudine, stavudine or abacavir.

14. The method of claim 4, wherein the non-nucleoside reverse transcriptase inhibitor is nevirapine, efavirenz or delavirdine.

15. The method of claim 4, wherein the phosphonate reverse transcriptase inhibitor is tenofovir.

16. The method of claim 4, wherein the compound of the TIBO-type is (S)-8-chloro-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo-[4,5,1-jk][1,4] benzo-diazepine-2(1H)-thione.

17. The method of claim 4, wherein the compound of the [alpha]-APA type is [alpha]-[(2-nitrophenyl)amino]-2,6-dichlorobenzene-acetamide.

18. The method of claim 4, wherein the inhibitor of trans-activating proteins is a TAT-inhibitor.

19. The method of claim 4, wherein the protease inhibitor is indinavir, ritonavir, saquinavir, lopinavir (ABT-378), nelfinavir, amprenavir, TMC-126, BMS-232632, or VX-175.

20. The method of claim 4, wherein the fusion inhibitor isT-20 or T-1249.

21. The method of claim 4, wherein the CXCR4 receptor antagonist is AMD-3100.

22. The method of claim 4, wherein the ribonucleotide reductase inhibitor is hydroxyurea.

Description

FIGURES

[0033] FIG. 1: SGT1 silencing inhibits HIV-1 replication without affecting CD4 and CXCR4 expressions in HeLa CD4+CXCR4+. HeLa CD4.sup.+CXCR4.sup.+LTR-Lac-Z.sup.+ cells were silenced (si-SGT1-1 and si-SGT1-2) or not (siRNA-CTR) for SGT1 with two different siRNAs. (A) At 48 hours post-siRNA transfection: SGT1 silencing was verified by Western blot analysis. (B) At 48 hours post-siRNA transfection: silenced cells were infected with NL4.3 X4 HIV-1 at MOI 1. Infections were determined at 24 hours post-infection by measuring the beta-galactosidase activity with respect to control cells (siCTR). (C) Cytotoxicity effects of siSGT1-1 and siSGT1-2 siRNAs were controled by the MTT assay with respect to control siRNA (siCTR) at 48 hours and 96 hours post- siRNA transfection. (D) At 72 hours post infection, HIV-1 productions were determined by quantifying CAp24 by ELISA from the cell supernatant of SGT1 silenced cells (siSGT1-1) and control cells (siCTL). The expressions of CD4 and CXCR4 receptors on the membrane of HeLa CD4+CXCR4+LTR-Lac-Z+ cells silenced (siSGT1-1) or not (siCTR) for SGT1 were controlled by Flow cytometry analysis of life cells at 48 hours post siRNA transfections for the percentage (E) and the mean fluorescence intensity (MFI) (F).

[0034] FIG. 2: SGT1 silencing inhibits HIV-1 replication in primary Monocytes Derived Macrophages (MDM). MDM from three different healthy donors (EFS7, EFS10 and EFS17) were transfected with smart pool siRNAs targeting SGT1 gene (siSGT1). Control MDM were transfected with a pool of non-targeting siRNAs (siCTL). (A-C top panels) At 96 hours post-siRNA transfection SGT1 silencing in MDM of different donors was verified by Western blot analysis. (A-C middle panels). At 96 hours post-siRNAs transfection: silenced MDM were infected with AD8 HIV-1 R5 virus (10 ng p24 for 1×10.sup.6 MDM). At 72 hours post infections, HIV-1 productions were determined by quantifying CAp24 by ELISA from the cell supernatant of SGT1 silenced MDM (siSGT1) and control cells (siCTL). The data are means±SD of triplicate wells. (A-C bottom panels) Cytotoxicity effects of SGT1 silencing mediated by siSGT-1 siRNAs transfections comparing to control cells were controlled by the WST-1 cell proliferation assay at 96 hours post-siRNAs transfections. The data are means±SD of triplicate wells.

[0035] FIG. 3: SGT1 silencing inhibits HIV-1 replication in activated CD4 T cells. Activated CD4 T cells from two healthy donors (EFS13 and EFS20) were transfected with smart pool siRNAs targeting SGT1 gene (siSGT1). Control cells were transfected with a pool of non-targeting siRNAs (siCTL). (A and B top panels) At 72 hours post-siRNA transfection SGT1 silencing in T lymphocytes was verified by Western blot analysis. (A and B middle panels) At 72 hours post-siRNAs transfection: silenced activated CD4 were infected with NL4.3 HIV-1 X4 virus (100 ng p24 for 1×10.sup.6 CD4 T cells). At 72 hours post infections, HIV-1 productions were determined by quantifying CAp24 by ELISA from the cell supernatant of SGT1 silenced lymphocytes (siSGT1) and control cells (siCTL). The data are means±SD of triplicate wells. (A bottom panel) Cytotoxicity effects of SGT1 silencing mediated by siSGT-1 siRNAs transfections comparing to control cells (siCTL) were controlled by the WST-1 cell proliferation assay at 72 hours post-siRNAs transfections. The data are means±SD of triplicate wells. (B bottom panel) Cytotoxicity effects of SGT1 silencing mediated by siSGT-1 siRNAs transfections comparing to control cells (siCTL) were controlled by measuring the lactate dehydrogenase activity in the supernatant of cells at 72 hours post-siRNAs transfections. The data are means±SD of triplicate wells.

[0036] FIG. 4: SGT1 silencing inhibits reverse transcription and nuclear import. (A and B) MDM from two different healthy donors (EFS10 and EFS17) and activated T cells from two donors (EFS13 and EFS20) were transfected with smart pool siRNAs targeting SGT1 gene (siSGT1). Control cells were transfected with a pool of non-targeting siRNAs (siCTL). MDM and activated T cells were infected at 96 hours and 72 hours, respectively, post-silencing with NL4.3 delta Env-Luc (VSV-G) HIV-1 strain (10 ng p24 for 1×10.sup.6 MDM and 100 ng p24 1×10.sup.6 activated T cells). Viral infectivity was determined by Luciferase activity at 72 hours post-infection. The data are means±SD of triplicate wells. In FIGS. 3 and 4 the same donors were infected in parallel with replication competent R5 or X4 viruses. (C, D, E and F) MDM from two different healthy donors (EFS27 and EFS29) and activated T cells from one donor (EFS30) were transfected with smart pool siRNAs targeting SGT1 gene (siSGT1). Control cells were transfected with a pool of non-targeting siRNAs (siCTL). MDM and activated T cells were infected at 96 hours and 72 hours post-silencing, respectively, with NL4.3 delta Env-Luc (VSV-G) HIV-1 strain pre-treated with Dnase I (10 ng p24 for 1×10.sup.6 MDM and 100 ng p24 for 1×10.sup.6 activated T cells). MDM and activated T cells were harvest at 24 hours and 6 hours post-infection, respectively, to analyze HIV-1 early reverse transcripts by qPCR. At 72 hours and 24 hours post-infection, MDM and activated T cells were harvest, respectively, to analyze HIV-1 Late Reverse Transcripts by qPCR. For HIV-1 two-LTRs circles analysis by qPCR, MDM and activated T cells were harvest at 72 hours and 24 hours, respectively. The integrated HIV-1 proviruses were determined by Alu-nested qPCR at 72 hours and 24 hours post-infection of MDM and activated CD4 T cells, respectively. The primers, probes and experimental procedure of HIV-1 DNA qPCR were previously described in Allouch et al-2013-PNAS and David et al-2006-journal of Immunology.

EXAMPLE

[0037] The protein SGT1 is an indispensable cellular factor for HIV-1 replication. In order to identify new proteins involved in the early steps of HIV-1 replication we characterized the role of SGT1 which is a protein that was described to have a role in the innate immune response in plants and in mammals [12, 13]. Indeed, SGT1 (suppressor of G2 allele of skp1) was described to be a co-chaperone of Heat Shock protein 90 (HSP90) and plays a role in the stabilization, maturation and activation of NLR proteins [14-16]. NLR (nucleotide binding domain and leucine-rich repeat containing) proteins provide pathogen-sensing systems that are conserved in plants and in animals [14, 16]. They can be activated directly or indirectly by pathogen derived molecules and cellular stress [14, 17]. Although SGT1 is highly conserved in eukaryotes [18], its precise role remains unclear as it controls a number of unrelated processes ranging from yeast/human kinetochore assembly [18, 19] to the activation of ubiquitin ligases [18], adenylyl cyclase and polo kinases [20]. To explore the role of SGT1 in HIV-1 infection, SGT1 was silenced with two different small interfering RNA (siSGT1-1 and siSGT1-2) that efficiently reduce expression of both SGT1 isoforms in HeLa cell lines that express stably the chemokine receptor CD4 and co-receptor CXCR4 and a LacZ gene under the HIV-1 LTR promoter (HeLa CD4.sup.+CXCR4.sup.+LTR-LacZ.sup.+)(FIG. 1A). Then HeLa CD4.sup.+CXCR4.sup.+LTR-LacZ.sup.+ cells were infected with the NL.sub.4.3 (X4) envelope (Env) HIV-1 replication competent virus. The HIV-1 infectivity was determined at 24 hours post-infection by measuring the β-galactosidase activity from LTR-LacZ reporter gene that is activated by viral Tat protein from the HIV-1 viral particles that infect cells. Importantly, HIV-1 infectivity was significantly reduced in three independent experiments, by 80 to 90% in the cells silenced with the two different SGT1 siRNAs (siSGT1-1 and siSGT1-2) comparing to control cells transfected with control siRNA (siCTR) (FIG. 1B). In these experiments, cell viability was controlled by measuring cytotoxicity (using MTT test) and we did not detect any cytotoxic effect of SGT1 silenced cells with respect to control cells (FIG. 1C) indicating that SGT1 silencing affected directly HIV-1 infectivity.

[0038] The replication of NL.sub.4.3 (X4) Env HIV-1 virus in SGT1 silenced HeLa cells was also determined by the quantification of the produced HIV-1 in the supernatant of cells at 72 hours post-infection by the HIV-1 CAp24 ELISA. Results reported in FIG. 1D showed that NL4.3 HIV-1 production, as quantified for CAp24 antigen content, was reduced by 94% in the supernatant of SGT1 silenced cells (siSGT1-1) comparing to control cells (siCTR) further demonstrating that the depletion of SGT1 abrogates HIV-1 replication. In order to understand whether SGT1 knockdown affects the expressions of CD4 and CXCR4 chemokine receptors on the cell surface of CD4.sup.+CXCR4.sup.+LTR-LacZ.sup.+ cells, we analyzed by Flow cytometry the percentage of cells expressing both receptors and the intensity of their expressions following SGT1 knockdown at 48 hours post siRNA transfection. No significant differences were found neither in the percentage of cells expressing CD4 and CXCR4 (FIG. 1E) nor in the receptors expressions intensities (FIG. 1F) following the silencing of SGT1. This result indicates that the depletion of SGT1 inhibits HIV-1 replication without affecting expressions of CD4 and CXCR4 receptors. All the above data strongly suggest that SGT1 is a crucial factor for HIV-1 replication.

[0039] We then validated the role of SGT1 during HIV-1 infection of primary cells targets of HIV-1 (macrophages and activated CD4 T cells). Monocyte Derived Macrophages (MDM) were differentiated from Peripheral Blood Mononuclear Cells (PBMCs) obtained from buffy coats of different healthy donors of Etablissement Français du Sang (EFS). Macrophages were silenced for SGT1 through the transfection of smart pool siRNAs containing four different siRNAs targeting SGT1 gene (siSGT1). Control cells were transfected with a pool of non-targeting siRNAs (siCTL). After 96 hours of transfection, macrophages were infected with AD8 HIV-1 viral strain (that has R5 type Env).

[0040] The efficiency of HIV-1 infection was determined by measuring the release of p24CA in the supernatant of macrophages infected during 72 hours. Results reported in FIGS. 2A-C (left panels) showed that with the protocol that we set up for silencing SGT1 in macrophages we obtained an efficient depletion of the protein in three different healthy donors (EFS7, EFS10 and EFS17). Importantly, the silencing of SGT1 in MDM from two donors completely abrogated HIV-1 replication and in one donor (EFS7) (where the SGT1 silencing is less efficient than EFS10 and EFS17) the replication was inhibited by 60% (FIGS. 3A-C middle panels). No cytotoxic effect of SGT1 silencing was detected (using WST1 assay) (FIGS. 3A-C, right panels). These results are representative of additional three different donors. Altogether, these data confirmed previous results and revealed that SGT1 is a crucial cellular protein of HIV-1 replication in macrophages.

[0041] We also developed a protocol for silencing SGT1 in activated T Lymphocytes. T cells were obtained from PBMCs of healthy donors of Etablissement Français du Sang (EFS) and then activated by PHA for 24 hours. At five days post-activation, T cells were transfected with smart pool siRNAs targeting SGT1 (siSGT1). Control T lymphocytes were transfected with a pool of non-targeting siRNAs (siCTL). At 72 hours post-siRNAs transfection, activated T cells were infected with NL.sub.4.3 (X4) Env HIV-1 virus. Viral replication was determined by quantifying CAp24 of the produced HIV-1 in the supernatant of T lymphocytes at 72 hours post-infections. FIG. 2 (A and B top panels) showed that efficient depletion of SGT1 in activated CD4 T cells was obtained from two donors (EFS13 and EFS20) with the set up silencing protocol. Interestingly, the depletion of SGT1 inhibited HIV-1 replication by 95% (FIG. 3 A and B, middle panels) without affecting cellular proliferation as measured by WST-1 assay (FIG. 3A, bottom panel) and without causing cytotoxicity as measured by lactate dehydrogenase (LDH) activity in the supernatant of transfected T lymphocytes (FIG. 3B, bottom panel). These data are consistent with results obtained in macrophages (FIG. 2) and further indicate that SGT1 is an indispensable cellular protein for HIV-1 replication in the main virus target cells activated T cells and macrophages (for both X4 and R5 viruses).

[0042] Silencing effects of SGT1 on HIV-1 infection were unexpected for us because SGT1 was described to be involved in the innate immune response by stabilizing NLR proteins and we hypothesized that by depleting SGT1, HIV-1 infection will be enhanced. However, SGT1 silencing with two different siRNAs in HeLa CD4.sup.+CXCR4.sup.+ cells and with a pool of 4 different siRNAs in macrophages and activated CD4 T cells inhibited HIV-1 infection without affecting cell viability led us to suggest that SGT1 promotes HIV-1 infection.

[0043] SGT1 promotes HIV-1 replication at the early post-entry steps: reverse transcription and nuclear import. In order to identify the replication step(s) in which HIV-1 uses SGT1 to perform its replication cycle, we studied the effect of SGT1 depletion in macrophages and in activated T lymphocytes on the different viral steps. To determine whether the viral entry step is involved, SGT1 depleted macrophages and activated T cells infected with R5 and X4 Env HIV-1 viruses, respectively, (results shown in FIGS. 2 and 3) were infected in parallel with HIV-1 strain that is deleted in Env and pseudotyped with VSV-G envelope and expressing luciferase as reporter gene (NL4.3 delta Env-Luc). The data shown in FIG. 4A and 4B indicate that the siRNA-mediated knockdown of SGT1 in MDM from two donors (EFS 10 and EFS17) and in activated CD4 T cells from two donors (EFS13 and EFS20) strongly inhibited HIV-1 infectivity, as determined by luciferase activity at 72 hours post-infection, of NL4.3 delta Env-Luc (VSV-G) HIV-1 viral strain. This inhibition is at the same extent with that observed with the replication competent HIV-1 viruses (R5 and X4) (FIGS. 2 and 3) and indicates that SGT1 depletion is not affecting viral entry step. These data are representative of five and three additional donors for macrophages and activated T cells, respectively.

[0044] To determine whether SGT1 is involved in the viral post-entry steps, we measured by quantitative Real Time PCR (qPCR) the different HIV-1 cDNA species (early and late reverse transcripts, 2-LTR circles and integrated proviruses) in macrophages and activated T cells silenced for SGT1 and infected with NL4.3 delta Env-Luc (VSV-G) HIV-1. As shown in FIG. 4C, 4D, 4E and 4F, SGT1 silencing does not affect early reverse transcripts (left panels), decreased late reverse transcripts by 50% (middle-left panels) and strongly inhibited 2-LTRs circles (middle-right panels) and integrated proviruses (right panels) by 90% to 100% in macrophages (from two donors, EFS27 and EFS29) and in activated T cells (from one donor, EFS30). The 2-LTRs circles of HIV-1 are formed in the nucleus by the non-homologous- end- joining (NHEJ) recombination of the 5′ and 3′ LTR DNA ends of the linear viral cDNA that succeed to enter the nucleus but fail to integrate into the human genome. Therefore, the presence of 2-LTRs circles are considered as a hallmark of viral nuclear import and their absence indicate a block at the level of nuclear import.

[0045] Datas obtained in FIG. 4 suggested that SGT1 knokdown has a first minor block at the level of the accomplishment of viral reverse transcription followed by a stronger block at the level of nuclear import which consequently abrogates HIV-1 integration. Altoghether these results indicate that SGT1 is a cellular factor that promotes early post-entry HIV-1 viral steps. All the SGT1 knockdowns presented in this virological part were controlled for cytotoxcity effects of silencing by both WST-1 proliferation assay and for the LDH activity in the supernatant of silenced cells and do not show any cytotoxic effect in the two different cell types: MDM and T lymphocytes.

[0046] SGT1 stabilizes HIV-1 integrase expression. Based on the results obtained in FIG. 4, we hypothesized that SGT1 stabilizes the expression of the viral and cellular proteins that are components of the Reverse Transcription (RTC) and the pre-integration (PIC) complexes and thus promotes the efficient accomplishment of viral cDNA synthesis and nuclear import. We started to test this hypothesis by monitoring the protein expression of the HIV-1 proteins: Nucleocapsid (NC) tagged with hemagglitinin epitope tag (HA), the HA tagged Integrase (HA-IN) and the accessory Viral protein r (Vpr) tagged with the Green Fluorescent Protein (GFP) with simultaneous co-expression of an exogenous human untagged SGT1 (UN-SGT1) in HEK293T cells through transfection of the indicated protein cDNA. Control cells were co-transfected with an untagged GFP (UN-GFP). Interestingly, we observed in three independent experiments that the expression HIV-1 Integrase (HA-IN) was considerably enhanced when SGT1 was over-expressed in HEK293T cells, while the expressions of Nucleocapsid or Vpr were unchanged under these conditions. These data indicate that SGT1 may stabilize the expression of the viral integrase.

CONCLUSION

[0047] Our results demonstrated that SGT1 is an indispensable cellular factor that promotes pre-integrative early steps of HIV-1 replication (reverse transcription and nuclear import). In attempt to search molecular mechanisms, we demonstrated that SGT1 stabilizes the expression of the viral integrase (IN), which is one of the important components of HIV-1 pre-integration complex [21, 22]. Interestingly, HIV-1 integrase has been shown to have roles in HIV-1 cDNA synthesis and nuclear import due to its direct interaction with the viral reverse transcriptase and to the cellular factors that are important for the virus nuclear translocation [22, 23].

REFERENCES

[0048] Throughout this application, various references describe the state of the art to which this invention pertains. The disclosures of these references are hereby incorporated by reference into the present disclosure.

[0049] 1. Peterlin, B. M. and D. Trono, Hide, shield and strike back: how HIV-infected cells avoid immune eradication. Nat Rev Immunol, 2003. 3(2): p. 97-107.

[0050] 2. Bergamaschi, A. and G. Pancino, Host hindrance to HIV-1 replication in monocytes and macrophages. Retrovirology, 2010. 7: p. 31.

[0051] 3. Goff, S. P., Host factors exploited by retroviruses. Nat Rev Microbiol, 2007. 5(4): p. 253-63.

[0052] 4. Rasaiyaah, J., et al., HIV-1 evades innate immune recognition through specific cofactor recruitment. Nature, 2013. 503(7476): p. 402-5.

[0053] 5. Yeung, M. L., et al., A genome-wide short hairpin RNA screening of jurkat T-cells for human proteins contributing to productive HIV-1 replication. J Biol Chem, 2009. 284(29): p. 19463-73.

[0054] 6. Zhou, H., et al., Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe, 2008. 4(5): p. 495-504.

[0055] 7. Konig, R., et al., Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell, 2008. 135(1): p. 49-60.

[0056] 8. Friedrich, B. M., et al., Host factors mediating HIV-1 replication. Virus Res, 2011. 161(2): p. 101-14.

[0057] 9. Jolly, C., I. Mitar, and Q. J. Sattentau, Adhesion molecule interactions facilitate human immunodeficiency virus type 1-induced virological synapse formation between T cells. J Virol, 2007. 81(24): p. 13916-21.

[0058] 10. Su, B., et al., Neutralizing antibodies inhibit HIV-1 transfer from primary dendritic cells to autologous CD4 T lymphocytes. Blood, 2012. 120(18): p. 3708-17.

[0059] 11. Christ, F. and Z. Debyser, The LEDGF/p75 integrase interaction, a novel target for anti-HIV therapy. Virology, 2013. 435(1): p. 102-9.

[0060] 12. Boter, M., et al., Structural and functional analysis of SGT1 reveals that its interaction with HSP90 is required for the accumulation of Rx, an R protein involved in plant immunity. Plant Cell, 2007. 19(11): p. 3791-804.

[0061] 13. Mayor, A., et al., A crucial function of SGT1 and HSP90 in inflammasome activity links mammalian and plant innate immune responses. Nat Immunol, 2007. 8(5): p. 497-503.

[0062] 14. Kadota, Y., K. Shirasu, and R. Guerois, NLR sensors meet at the SGT1-HSP90 crossroad. Trends Biochem Sci, 2010. 35(4): p. 199-207.

[0063] 15. da Silva Correia, J., et al., Regulation of Nod1-mediated signaling pathways. Cell Death Differ, 2007. 14(4): p. 830-9.

[0064] 16. Schroder, K. and J. Tschopp, The inflammasomes. Cell, 2010. 140(6): p. 821-32.

[0065] 17. Khachatryan, V., et al., Search for quark compositeness with the dijet centrality ratio in pp collisions at radicals=7 TeV. Phys Rev Lett, 2010. 105(26): p. 262001.

[0066] 18. Kitagawa, K., et al., SGT1 encodes an essential component of the yeast kinetochore assembly pathway and a novel subunit of the SCF ubiquitin ligase complex. Mol Cell, 1999. 4(1): p. 21-33.

[0067] 19. Steensgaard, P., et al., Sgt1 is required for human kinetochore assembly. EMBO Rep, 2004. 5(6): p. 626-31.

[0068] 20. Martins, T., et al., Sgt1, a co-chaperone of Hsp90 stabilizes Polo and is required for centrosome organization. EMBO J, 2009. 28(3): p. 234-47.

[0069] 21. Zhan, P., X. Liu, and E. De Clercq, Blocking nuclear import of pre-integration complex: an emerging anti-HIV-1 drug discovery paradigm. Curr Med Chem, 2010. 17(6): p. 495-503.

[0070] 22. Taltynov, O., et al., Cellular cofactors of lentiviral integrase: from target validation to drug discovery. Mol Biol Int, 2012. 2012: p. 863405.

[0071] 23. Chakraborty, A., et al., Biochemical interactions between HIV-1 integrase and reverse transcriptase. FEBS Lett, 2013. 587(5): p. 425-9.

[0072] 24. Zhang, M., et al., Structural basis for assembly of Hsp90-Sgt1-CHORD protein complexes: implications for chaperoning of NLR innate immunity receptors. Mol Cell, 2010. 39(2): p. 269-81.

[0073] 25. Noel, L.D., et al., Interaction between SGT1 and cytosolic/nuclear HSC70 chaperones regulates Arabidopsis immune responses. Plant Cell, 2007. 19(12): p. 4061-76.